Results 81 to 90 of about 137,573 (297)

Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome

open access: yesArthritis Care &Research, EarlyView.
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino   +9 more
wiley   +1 more source

Effect of Implementing a Dashboard With or Without a Best Practice Alert on HLA‐B*58:01 Testing Rates Among Allopurinol Users at VA Medical Centers

open access: yesArthritis Care &Research, EarlyView.
Objective The American College of Rheumatology recommends HLA‐B*58:01 allele testing before the initiation of allopurinol, specifically among Asian and African American/Black patients, due to their increased risk for severe hypersensitivity reactions. However, testing rates remain low at many health care facilities.
Abimbola Fadairo‐Azinge   +6 more
wiley   +1 more source

Study highlights long-term prescription drug use. [PDF]

open access: yes, 2018
One-third of medical card patients receive long-term prescriptions for drugs that can lose their effect and cause problems such as falls, according to the first detailed analysis of benzodiazepine and Z-drug prescribing in Ireland.....
Shanahan, Catherine
core  

Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches [PDF]

open access: yes, 2013
The persistent lack of information on the paediatric use of most medicinal products is a major hindrance towards an optimal treatment of paediatric patients.
S. Antoniazzi   +8 more
core   +1 more source

Drug prescription before and after implementation of a CPOE system on the Paediatric Intensive Care Unit: a quality improvement study

open access: yesSwiss Medical Weekly
STUDY AIMS: Paediatric drug prescription is complex, especially in the paediatric intensive care unit (PICU), where errors may be particularly harmful due to frequent use of high-risk medications.
Rebecca Angresius   +5 more
doaj   +1 more source

Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. [PDF]

open access: yes, 2006
Item does not contain fulltextBACKGROUND: The prevention of drug-drug interactions requires a systematic approach for which the concept of clinical risk management can be used.
Dep Farmaceutische wetenschappen   +5 more
core   +1 more source

Paediatric off-label use of drugs in Gansu, China: a multicentre cross-sectional study

open access: yesBMJ Open
Objective To examine the current prevalence and cost of paediatric off-label drug prescriptions in Gansu, China, and the potential influencing factors.Design The prevalence of off-label prescriptions in paediatrics was evaluated according to the National
Xufei Luo   +12 more
doaj   +1 more source

Preventable adverse drug events in critically ill HIV patients: Is the detection of potential drug-drug interactions a useful tool?

open access: yesClinics, 2018
OBJECTIVES: The aim of this study was to develop a strategy to identify adverse drug events associated with drug-drug interactions by analyzing the prescriptions of critically ill patients.
Grazielle Viana Ramos   +3 more
doaj   +1 more source

Risk of Retinopathy Associated with Long‐Term Use of Hydroxychloroquine in Patients with Rheumatic Diseases: A Systematic Review and Meta‐Analysis

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to estimate the prevalence and cumulative incidence of hydroxychloroquine retinopathy (HCQ‐R) and its risk factors among patients receiving long‐term HCQ with rheumatic diseases through a systematic review and meta‐analysis of observational studies that used spectral‐domain optical coherence tomography (SD‐OCT) for screening ...
Narsis Daftarian   +4 more
wiley   +1 more source

Stagnation in the Drug Development Process: Are Patents the Problem? [PDF]

open access: yes
The rate of new drug development has stagnated, in spite of large increases in both private and public sector spending on biomedical research. The flip side of slower progress is higher drug costs.
Dean Baker
core  

Home - About - Disclaimer - Privacy